NDAINJECTIONINJECTABLEPriority Review
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCAMTIN (topotecan hydrochloride) is a topoisomerase I inhibitor administered intravenously as a cytotoxic chemotherapy agent. It works by binding to topoisomerase I-DNA complexes and preventing re-ligation of single-strand DNA breaks, leading to double-strand breaks during DNA synthesis that mammalian cells cannot efficiently repair. The drug is indicated for solid tumors where topoisomerase I inhibition provides clinical benefit.
LOE Approaching
Product faces declining exclusivity with moderate competitive pressure (30/100), signaling defensive positioning and likely team consolidation rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Started Mar 2015
178 enrolled
Adult LiposarcomaMetastatic LiposarcomaMetastatic Osteosarcoma+4 more
Regulatory Hycamtin(Oral) PMS
Started Oct 2010
92 enrolled
Lung Cancer, Small Cell
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Started Dec 2006
472 enrolled
Lung Cancer, Non-Small Cell
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
Started Jun 2005
33 enrolled
Lung Cancer, Small Cell
Worked on HYCAMTIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.